Name: Edwards Lifesciences Corp. (NYSE:EW) | Cash Flow Statement (Quarterly)
Creator: Stock Analysis on Net

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Download chart

Edwards Lifesciences Corp., consolidated cash flow statement (quarterly data)

US$ in thousands

3 months ended:	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017
Net income (loss)	335,300)	340,100)	489,500)	338,200)	309,500)	325,200)	(121,900)	310,600)	280,200)	274,700)	242,300)	249,700)	7,000)	225,900)	282,700)	206,600)	(2,800)	170,100)	186,100)	230,200)
Depreciation and amortization	33,000)	33,600)	35,800)	32,400)	32,600)	25,600)	24,500)	24,500)	23,900)	23,100)	21,700)	20,600)	19,900)	19,200)	19,200)	19,100)	21,200)	20,700)	18,900)	21,100)
Non-cash operating lease cost	7,100)	7,100)	7,000)	7,300)	7,500)	7,400)	6,600)	6,700)	6,600)	6,900)	6,100)	5,700)	—)	—)	—)	—)	—)	—)	—)	—)
Stock-based compensation	24,200)	26,600)	30,300)	28,200)	20,900)	23,000)	24,800)	23,900)	18,400)	19,800)	22,300)	20,800)	16,000)	17,400)	19,200)	18,400)	15,300)	15,800)	15,300)	15,200)
Inventory write off	—)	—)	—)	—)	—)	—)	—)	—)	—)	26,900)	46,200)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Impairment charges	—)	—)	—)	—)	—)	—)	—)	—)	40,600)	—)	—)	—)	118,800)	—)	—)	—)	—)	—)	31,000)	—)
Change in fair value of contingent consideration liabilities	(18,100)	1,100)	(102,600)	(4,500)	5,200)	(9,000)	19,600)	(2,200)	(18,500)	(2,300)	8,000)	6,700)	(14,000)	(6,400)	10,900)	3,800)	2,600)	(16,700)	3,100)	1,100)
Deferred income taxes	(61,500)	3,900)	5,400)	10,800)	(11,600)	1,400)	(42,800)	3,600)	2,600)	(3,400)	7,100)	5,800)	(57,100)	10,900)	(12,200)	31,100)	(26,300)	400)	7,100)	36,600)
Purchase of intellectual property	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	24,000)	—)	—)	—)	—)	—)	1,000)	100)	5,600)
Other	(7,100)	(3,100)	(10,500)	(2,700)	(4,100)	(4,200)	(9,900)	14,700)	2,000)	2,900)	(700)	(7,000)	10,000)	1,000)	1,000)	1,000)	(4,000)	(1,200)	(400)	(600)
Accounts and other receivables, net	6,800)	38,000)	(46,400)	(89,500)	51,100)	(30,700)	25,700)	(4,200)	(17,700)	18,900)	(43,400)	(45,800)	(28,400)	(2,900)	(27,300)	29,900)	10,500)	56,100)	11,000)	(81,500)
Inventories	(6,600)	8,100)	15,000)	2,500)	(2,400)	(19,000)	(64,000)	(35,200)	(21,500)	(22,000)	(32,500)	(29,400)	(22,200)	(23,000)	(17,200)	(3,300)	(14,200)	(37,600)	(47,900)	(24,300)
Accounts payable and accrued liabilities	31,100)	79,300)	94,100)	(9,300)	(30,600)	81,400)	9,100)	(144,400)	45,700)	81,400)	231,600)	(242,200)	188,500)	93,200)	28,800)	(118,000)	36,600)	112,400)	30,400)	(94,200)
Income taxes	33,000)	5,800)	9,100)	14,100)	12,700)	(74,700)	(23,100)	32,200)	26,200)	20,500)	12,800)	(16,300)	50,800)	(19,700)	(182,200)	(6,700)	333,400)	(9,000)	(65,000)	19,000)
Prepaid expenses and other current assets	6,400)	1,100)	5,800)	(5,400)	(6,400)	(21,800)	5,400)	(5,700)	(4,300)	(6,400)	1,100)	2,800)	4,800)	22,400)	14,900)	(26,400)	(10,000)	(1,200)	4,900)	(3,600)
Litigation settlement accrual	(10,100)	(22,800)	2,100)	1,600)	1,300)	(98,700)	367,900)	—)	—)	—)	(180,000)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Other	100)	13,100)	(8,500)	(23,200)	14,300)	10,200)	9,300)	(17,500)	15,200)	(3,700)	(1,400)	6,100)	(1,100)	4,300)	2,400)	(4,200)	1,600)	—)	3,100)	3,700)
Changes in operating assets and liabilities	60,700)	122,600)	71,200)	(109,200)	40,000)	(153,300)	330,300)	(174,800)	43,600)	88,700)	(11,800)	(324,800)	192,400)	74,300)	(180,600)	(128,700)	357,900)	120,700)	(63,500)	(180,900)
Adjustments to reconcile net income (loss) to net cash provided by operating activities	38,300)	191,800)	36,600)	(37,700)	90,500)	(109,100)	353,100)	(103,600)	119,200)	162,600)	98,900)	(248,200)	286,000)	116,400)	(142,500)	(55,300)	366,700)	140,700)	11,600)	(101,900)
Net cash provided by operating activities	373,600)	531,900)	526,100)	300,500)	400,000)	216,100)	231,200)	207,000)	399,400)	437,300)	341,200)	1,500)	293,000)	342,300)	140,200)	151,300)	363,900)	310,800)	197,700)	128,300)
Capital expenditures	(89,800)	(60,700)	(69,300)	(106,000)	(113,200)	(103,300)	(108,300)	(82,200)	(71,500)	(76,100)	(64,600)	(42,200)	(57,600)	(85,100)	(52,800)	(43,200)	(51,900)	(42,300)	(58,000)	(15,900)
Deposit of cash in escrow	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(25,000)	—)	—)	—)
Purchases of held-to-maturity investments	(147,000)	(68,000)	(35,000)	—)	(50,000)	—)	—)	(112,000)	(100,200)	—)	—)	(30,000)	(20,000)	(190,000)	—)	—)	(88,000)	(211,300)	(505,600)	—)
Proceeds from held-to-maturity investments	68,000)	20,000)	—)	50,000)	—)	—)	112,000)	100,200)	—)	—)	30,000)	20,000)	190,000)	48,600)	101,000)	238,500)	321,700)	101,000)	2,500)	229,500)
Purchases of available-for-sale investments	(907,300)	(345,500)	(299,100)	(77,400)	(295,400)	(118,600)	(124,800)	(150,900)	(342,900)	(19,600)	(75,400)	—)	(134,000)	(115,300)	—)	—)	(52,000)	(145,500)	(164,900)	(167,400)
Proceeds from available-for-sale investments	129,100)	93,600)	81,700)	86,800)	206,500)	103,300)	127,200)	127,800)	81,600)	87,500)	134,700)	56,100)	30,100)	92,000)	58,800)	42,300)	67,700)	91,600)	96,100)	193,300)
Investments in intangible assets	(4,000)	—)	—)	—)	(300)	—)	—)	—)	—)	—)	(7,200)	(16,800)	—)	—)	—)	(3,000)	—)	(1,000)	(3,700)	(2,700)
Acquisitions	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(100,200)	—)	—)	—)	—)	—)	(108,000)	(100)	(2,800)	(82,000)
Payment for acquisition option	(7,400)	—)	(5,700)	—)	—)	—)	(10,000)	—)	—)	—)	—)	(35,000)	—)	—)	—)	—)	—)	—)	—)	—)
Issuances of notes receivable	(1,500)	—)	—)	(3,600)	(500)	(4,600)	(5,300)	(16,600)	(4,500)	(3,000)	(4,700)	(700)	—)	—)	—)	—)	—)	—)	—)	—)
Collections of notes receivable	10,000)	—)	10,000)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Other	(16,000)	(16,800)	(12,100)	500)	(7,000)	(3,100)	(1,000)	(1,000)	(7,800)	(1,500)	(900)	(900)	(2,800)	(4,400)	(2,100)	(14,300)	(15,200)	(1,900)	(1,800)	(3,600)
Net cash (used in) provided by investing activities	(965,900)	(377,400)	(329,500)	(49,700)	(259,900)	(126,300)	(10,200)	(134,700)	(445,300)	(12,700)	(88,300)	(49,500)	5,700)	(254,200)	104,900)	220,300)	49,300)	(209,500)	(638,200)	151,200)
Proceeds from issuance of debt	—)	(8,800)	9,500)	4,500)	3,900)	1,700)	2,700)	7,900)	6,900)	2,300)	6,000)	3,700)	1,600)	600)	680,700)	5,100)	5,400)	3,900)	608,000)	377,400)
Payments on debt and finance lease obligations	(100)	8,700)	(10,700)	(4,900)	(3,000)	(2,200)	(3,600)	(8,200)	(5,200)	(3,500)	(16,200)	(4,000)	(601,200)	(1,900)	(517,100)	(5,100)	(5,600)	(4,600)	(454,800)	(353,400)
Purchases of treasury stock	(96,500)	(1,800)	(111,900)	(302,600)	(200)	(1,400)	(9,000)	(614,800)	—)	(1,300)	(256,300)	(5,700)	(272,000)	(173,100)	(348,200)	(2,200)	(251,300)	(800)	(73,800)	(437,400)
Equity forward contract related to accelerated share repurchase agreement	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	80,000)	(80,000)	—)	—)	—)	—)	—)
Proceeds from stock plans	33,900)	38,900)	54,200)	31,600)	37,000)	36,100)	38,300)	29,100)	35,000)	39,000)	41,500)	45,000)	27,700)	35,000)	39,600)	44,700)	22,500)	22,600)	45,600)	23,100)
Payment of contingent consideration	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(15,100)	—)	—)	—)	—)	—)
Other	700)	2,000)	(100)	(2,900)	3,700)	(200)	(4,300)	(400)	300)	(2,100)	(6,400)	5,400)	(800)	2,700)	(600)	(1,600)	—)	(800)	1,800)	(1,000)
Net cash provided by (used in) financing activities	(62,000)	39,000)	(59,000)	(274,300)	41,400)	34,000)	24,100)	(586,400)	37,000)	34,400)	(231,400)	44,400)	(844,700)	(56,700)	(240,700)	40,900)	(229,000)	20,300)	126,800)	(391,300)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	1,800)	500)	(2,600)	14,200)	(10,600)	(3,300)	(4,500)	(2,100)	1,400)	800)	(3,900)	(1,300)	(1,200)	3,500)	(5,000)	(3,800)	3,800)	500)	2,600)	1,000)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(652,500)	194,000)	135,000)	(9,300)	170,900)	120,500)	240,600)	(516,200)	(7,500)	459,800)	17,600)	(4,900)	(547,200)	34,900)	(600)	408,700)	188,000)	122,100)	(311,100)	(110,800)

An analysis of the quarterly cash flow trends from March 2017 through December 2021 reveals a company with strong operational cash generation, an increasing commitment to capital expenditures, and an aggressive shareholder return strategy through share repurchases.

Operating Cash Flow Dynamics: Net cash provided by operating activities demonstrates a general upward trajectory, increasing from a range of 128 million to 364 million US dollars in 2017 to a peak of 531.9 million US dollars in September 2021. While net income exhibited significant quarterly volatility—including losses in December 2017 and June 2020—operational cash flows remained largely resilient. This stability is attributed to consistent non-cash adjustments, specifically depreciation and amortization, which grew from approximately 21 million US dollars per quarter in 2017 to 33 million US dollars by late 2021, and stock-based compensation, which trended upward from 15 million to 24 million US dollars.; Working capital fluctuations contributed significantly to quarterly variance. The "Changes in operating assets and liabilities" line item showed high volatility, particularly regarding accounts payable and accrued liabilities, which frequently shifted between large inflows and outflows, suggesting cyclical timing in payment obligations.
Investing Activities and Capital Allocation: Capital expenditures show a clear trend of expansion. Spending increased from an average of 30 million to 50 million US dollars per quarter in 2017 to a range of 60 million to 113 million US dollars in 2020 and 2021, indicating intensified investment in long-term productive assets.; Investment portfolio management is characterized by high activity in available-for-sale (AFS) and held-to-maturity (HTM) securities. A substantial increase in liquidity deployment is evident in December 2021, where purchases of AFS investments reached 907.3 million US dollars. Acquisitions remained sporadic, with notable outflows in December 2017 and June 2019.
Financing Activities and Capital Structure: Financing activities are dominated by a consistent and aggressive treasury stock repurchase program. Significant outflows for share buybacks were observed throughout the period, with a peak quarterly expenditure of 614.8 million US dollars in March 2020.; Debt activity was most pronounced in 2017 and 2018, characterized by large-scale issuances and subsequent repayments. From 2019 through 2021, debt issuance and repayment levels stabilized at significantly lower volumes, suggesting a shift toward utilizing internally generated operating cash to fund buybacks and investments rather than relying on new debt.

Overall, the financial profile is one of a mature organization using growing operational cash flows to fund both internal infrastructure growth and substantial returns to shareholders. The extreme volatility in the net increase or decrease of cash is primarily driven by the timing of large-scale investment purchases and share repurchase executions rather than operational instability.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?

Edwards Lifesciences Corp. (NYSE:EW)

Cash Flow StatementQuarterly Data

Cash Flow Statement
Quarterly Data